Following a dose reduction to 150 mg/day by 27 December 2023, another remarkable recovery was noted, with LVEF improving to 62%, NT-proBNP decreasing to 849 ng/L, and paroxysmal atrial fibrillation becoming less frequent. The gene discussed is NPPB; the disease is Paroxysmal atrial fibrillation.